Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | PPM1D | O15297 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16746024 | 1.00 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL22375300 | 1.00 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL16746021 | 1.00 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL22375301 | 0.95 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL16746019 | 0.95 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL16746020 | 0.95 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL22375302 | 0.95 | GAA (0.35) | GAASMN1; SMN2KCNA5PPM1D | |
| SCHEMBL26014619 | 0.74 | KCNA5 (0.50) | GAASMN1; SMN2KCNA5 | |
| SCHEMBL26014618 | 0.74 | KCNA5 (0.50) | GAASMN1; SMN2KCNA5 | |
| SCHEMBL5175578 | 0.73 | SMN1; SMN2 (0.46) | GAASMN1; SMN2KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340013-A1 | POLYPEPTIDES AND METHODS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20200271658-A1 | METHODS OF INCORPORATING AN AMINO ACID COMPRISING A BCN GROUP INTO A POLYPEPTIDE USING AN ORTHOGONAL CODON ENCODING IT AND AN ORTHORGONAL PYLRS SYNTHASE | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340013-A1 | POLYPEPTIDES AND METHODS | BCAT1, BCDIN3D, NPY1R | GAA 2156/4885SMN1; SMN2 3460/4885KCNA5 3816/4885 |
| US-20200271658-A1 | METHODS OF INCORPORATING AN AMINO ACID COMPRISING A BCN GROUP INTO A POLYPEPTIDE USING AN ORTHOGONAL CODON ENCODING IT AND AN ORTHORGONAL PYLRS SYNTHASE | NPY1R, YARS1, NPY2R | GAA 3710/4885SMN1; SMN2 3580/4885KCNA5 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.